Carvedilol vs nebivolol: which one is best?
In the ITP, nebivolol “was also found to produce a female-specific decline (4%, p = 0.03) in lifespan”. In males, there was also a borderline significant lifespan shortening. (poke @LukeMV) The ITP used 60 ppm, so 10 mg/kg body weight/day, so about 1 mg/kg for a human? That’s a lot! A previous study that used a lower dose (1 mg/kg body weight/day, for about 0.1 mg/kg for a human close to the average daily dose of 5 mg/day) found that: “The β-blockers metoprolol and nebivolol, administered in food daily beginning at 12 months of age, significantly increase the mean and median life span of isocalorically fed, male C3B6F1 mice, by 10 and 6.4 %, respectively (P < 0.05).” (β1-Adrenergic receptor blockade extends the life span of Drosophila and long-lived mice 2013) For metoprolol they used 30 mg/kg body weight/day, which is also close to the daily human dose (150 mg/day). So if you trust this earlier study, metoprolol is better than nebivolol at the normal human doses.
On the other hand, carvedilol led to a +25% but NOT statistically significant lifespan increase in the Ora Biomedical challenge. It worked wonders in early age but then had a detrimental effect:
(I think resting heart rate starts decreasing from age ~60, so maybe carvedilol shouldn’t be used in healthy people past that age? Or maybe it should only be used to reach a given resting heart rate threshold?)
Metoprolol was tested but at a dose probably too low, so nothing happened:
According to Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol) 2013: “Compared to β1-selective BBs used in HF (8 trials, n = 4,563), carvedilol significantly reduced all-cause mortality (risk ratio 0.85, 95% confidence interval 0.78 to 0.93, p = 0.0006). In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16). In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.”
One reason given to use nebivolol compared to other beta-blockers is the potential beneficial effect on erectile function. However, according to this paper (Effects of major antihypertensive drug classes on erectile function: a network meta-analysis 2022), although nebivolol might be better than non-vasodilatory beta-blockers (such as bisoprolol and metoprolol), there’s no difference between nebivolol and other vaso-dilatory beta-blockers (carvedilol and labetalol) in terms of erectile function.
Nebivolol is still the only beta-blocker that can increase nitric oxide. And carvedilol has a shorter half-life so it’s taken twice daily. Some countries have carvedilol SR, once daily. So there’s a tradeoff…